Jinhua Qinggan granule, a Chinese herbal medicine against COVID-19, induces rapid changes in the plasma levels of IL-6 and IFN-γ - Kageyama, Yasunari; Aida, Koichi; Kawauchi, Kimihiko; Morimoto, Masafumi; Ebisui, Tomoka; Akiyama, Tetsu; Nakamura, Tsutomu (medRxiv, 2020)
Background Currently, effective vaccines or specific therapeutic agents against COVID-19 are not available. However, in China, traditional Chinese herbal medicines have provided therapeutic benefit to patients with COVID-19. Jinhua Qinggan granule (JHQGG) is a Chinese multi-herbal formula previously developed for the treatment of H1N1 influenza and has been encouraged for patients clinically suspected of COVID-19 during medical observation. However, the immunological mechanism for the efficacy of JHQGG has not been confirmed.Objectives We thus examined whether the administration of JHQGG affects hematological and immunological measures in healthy individuals.Method We enrolled 18 healthy volunteers, all of whom tested negative for antibodies to SARS-CoV-2. Peripheral blood samples were collected 1 h after oral administration of JHQGG and subjected to hematological, biochemical, and cytokine tests.Results JHQGG rapidly induced a significant decrease in the plasma level of IL-6 and an increase in the plasma level of IFN-γ.Conclusions Our finding suggests that the therapeutic efficacy of JHQGG against COVID-19 is, in part, associated with its rapid immunomodulatory activity.Competing Interest StatementYasunari Kageyama, Koichi Aida, Kimihiko Kawauchi, Masafumi Morimoto, and Tomoka Ebisui are employees of Takanawa Clinic. Tetsu Akiyama and Tsutomu Nakamura have advisory roles in conducting clinical research in Takanawa Clinic and receive advisory fees from Takanawa Clinic.Clinical TrialUMIN000040407 We have prospectively registered our clinical trial on UMIN-CTR in May 15, 2020 prior to the start of the trial and has been opened the trial information to the public (https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000046108). We have described this information and the trial ID number (UMIN000040407) in our manuscript (refer to the Statement of Ethics section in page 4). UMIN-CTR (University Hospital Medical Information Network-Clinical Trials Registry) has been recognized by the ICMJE as an acceptable registry and is currently one of internationally recognized trial registries.Funding StatementThis research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All procedures were approved by the Ethics Committees of the Takanawa Clinic (approval number: 2020-2).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available on request from the corresponding author, TN. The data are not publicly available due to their containing information that could compromise the privacy of research participants.